Wedbush Forecasts Biogen's Q3 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities researchers at Wedbush reduced their Q3 2025 earnings per share estimates for shares of Biogen in a research note issued on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of $3.81 per share for the quarter, down from their previous forecast of $3.85. Wedbush has a "Neutral" rating and a $121.00 price objective on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen's Q4 2025 earnings at $4.11 EPS, Q1 2026 earnings at $4.01 EPS and Q3 2026 earnings at $3.93 EPS.

Other equities research analysts have also issued reports about the company. Canaccord Genuity Group reduced their price target on Biogen from $265.00 to $220.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Piper Sandler reaffirmed a "neutral" rating and set a $115.00 price objective on shares of Biogen in a research report on Thursday, June 12th. HC Wainwright reissued a "buy" rating and issued a $187.00 target price on shares of Biogen in a research report on Thursday, June 26th. Oppenheimer set a $205.00 price target on shares of Biogen in a report on Friday, May 2nd. Finally, Truist Financial decreased their price objective on shares of Biogen from $210.00 to $199.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Twenty analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $188.48.

Biogen Stock Up 0.8%

NASDAQ BIIB traded up $0.96 on Wednesday, reaching $128.46. The stock had a trading volume of 1,234,669 shares, compared to its average volume of 1,443,945. The company has a current ratio of 1.44, a quick ratio of 1.01 and a debt-to-equity ratio of 0.27. Biogen has a 1 year low of $110.04 and a 1 year high of $236.48. The business has a 50 day moving average price of $128.61 and a 200 day moving average price of $133.68. The company has a market capitalization of $18.82 billion, a price-to-earnings ratio of 12.68, a P/E/G ratio of 1.06 and a beta of 0.14.

Biogen (NASDAQ:BIIB - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). Biogen had a return on equity of 14.03% and a net margin of 15.07%. The company had revenue of $2.43 billion during the quarter, compared to analysts' expectations of $2.25 billion. During the same quarter in the previous year, the company earned $3.67 EPS. The firm's quarterly revenue was up 6.2% compared to the same quarter last year.

Insider Activity at Biogen

In other Biogen news, insider Rachid Izzar sold 2,223 shares of Biogen stock in a transaction on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total transaction of $300,105.00. Following the sale, the insider owned 6,330 shares in the company, valued at $854,550. The trade was a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.18% of the company's stock.

Institutional Trading of Biogen

Several institutional investors have recently made changes to their positions in the business. Signaturefd LLC lifted its stake in Biogen by 3.5% during the fourth quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company's stock worth $320,000 after purchasing an additional 71 shares during the period. Wedmont Private Capital raised its holdings in shares of Biogen by 3.8% in the 2nd quarter. Wedmont Private Capital now owns 2,190 shares of the biotechnology company's stock worth $291,000 after buying an additional 81 shares in the last quarter. Israel Discount Bank of New York lifted its position in shares of Biogen by 6.2% during the 4th quarter. Israel Discount Bank of New York now owns 1,405 shares of the biotechnology company's stock worth $215,000 after buying an additional 82 shares during the period. B. Riley Wealth Advisors Inc. boosted its stake in Biogen by 4.1% in the 4th quarter. B. Riley Wealth Advisors Inc. now owns 2,343 shares of the biotechnology company's stock valued at $358,000 after buying an additional 92 shares in the last quarter. Finally, Quent Capital LLC boosted its stake in Biogen by 31.2% in the 1st quarter. Quent Capital LLC now owns 391 shares of the biotechnology company's stock valued at $54,000 after buying an additional 93 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.